SCHEMBL22402900

SCHEMBL22402900

O=C(O)CCCCNC(=O)COc1c(-c2csc(N3CCOCC3)n2)ccc(F)c1F

nearest known ligand 0.59

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 13/20 0.59
▸ VHL P40337 1/20 0.54
▸ RAB9A P51151 4/20 0.39
▸ NPC1 O15118 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ LMNA P02545 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ HSD17B10 Q99714 1/20 0.37
▸ MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22263271 0.94 AR (0.61) ARVHLRAB9ANPC1ALDH1A1
SCHEMBL22263332 0.93 AR (0.60) ARVHLRAB9ANPC1ALDH1A1
Hydrochloric Acid SCHEMBL22263254 0.91 AR (0.60) ARVHLRAB9ANPC1ALDH1A1
SCHEMBL23846235 0.90 AR (0.61) ARVHLRAB9ANPC1LMNA
Hydrochloric Acid SCHEMBL30938120 0.90 AR (0.59) ARVHLRAB9ANPC1ALDH1A1
Hydrochloric Acid SCHEMBL30938119 0.90 AR (0.59) ARVHLRAB9ANPC1ALDH1A1
Hydrochloric Acid SCHEMBL22263225 0.90 AR (0.59) ARVHLRAB9ANPC1ALDH1A1
SCHEMBL26458194 0.89 AR (0.60) ARVHLRAB9ANPC1ALDH1A1
SCHEMBL27412012 0.88 AR (0.66) ARVHLRAB9ANPC1LMNA
SCHEMBL28654521 0.88 AR (0.56) ARVHLRAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230241227-A1 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR DBD THERAPEUTICS, LLC 2023-08-03 — — US disclosed
US-20230132823-A1 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR DBD THERAPEUTICS, LLC 2023-05-04 — — US disclosed
US-11547759-B2 Bi-functional compounds and methods for targeted ubiquitination of androgen receptor MONTELINO THERAPEUTICS, INC. (US) 2023-01-10 — — US disclosed
US-20200282068-A1 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR DBD THERAPEUTICS, LLC 2020-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230241227-A1 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR AR, ADRM1, PSMA3 AR 1/4885VHL 491/4885RAB9A 3512/4885
US-20200282068-A1 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR AR, ADRM1, PSMA3 AR 1/4885VHL 491/4885RAB9A 3512/4885
US-11547759-B2 Bi-functional compounds and methods for targeted ubiquitination of androgen receptor AR, ADRM1, PSMA3 AR 1/4885VHL 525/4885RAB9A 3327/4885
US-20230132823-A1 BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR AR, ADRM1, PSMA3 AR 1/4885VHL 525/4885RAB9A 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback